This Week in Infectious Disease — Jul 18, 2026

Welcome to This Week in Infectious Disease. This week we're covering 6 notable papers spanning major clinical themes, including the optimization of treatment for opportunistic infections in vulnerable pediatric and adult populations, the evolving landscape of antimicrobial resistance and diagnostic speed, and the public health tradeoffs of expanding preventative therapies. Let's dive in.

We begin with a focus on managing opportunistic and severe infections in highly vulnerable patient populations. In a major publication from The Lancet, researchers reported the results of the EMPIRICAL trial, a multicentre, open-label, group-sequential, factorial, randomized, controlled, superiority trial conducted across nineteen hospitals in Côte d'Ivoire, Malawi, Mozambique, Uganda, Zambia, and Zimbabwe [1]. This trial evaluated whether empirical valganciclovir treatment for cytomegalovirus improves survival in infants living with HIV who are hospitalized with severe pneumonia. The study enrolled five hundred and sixty-three infants aged twenty-eight to three hundred and sixty-five days, randomizing them to receive either standard of care—which included standard treatments for bacterial and Pneumocystis jirovecii pneumonia—or standard of care plus fifteen days of oral valganciclovir, or standard of care plus empirical tuberculosis treatment, or both interventions combined. Analyzing the valganciclovir comparison groups, the researchers found that valganciclovir did not show a statistically significant reduction in all-cause mortality when evaluated via traditional intention-to-treat analysis at the primary endpoints. Specifically, at day fifteen, twenty-three percent of infants in the valganciclovir group died compared to twenty-seven percent in the groups without valganciclovir. By twelve months, mortality rates were forty-three percent and forty-eight percent, respectively. However, when the investigators applied a time-varying effects model, they observed a significant early survival benefit, with valganciclovir associated with a forty percent reduction in the adjusted hazard of death at day fifteen. This survival benefit remained notable over one year when excluding early deaths that occurred within the first forty-eight hours of treatment initiation. Reassuringly, severe adverse events were not more common in the valganciclovir arm, suggesting that empirical valganciclovir represents a safe and potentially life-saving early intervention for high-risk infants in these settings.

In a parallel effort to understand opportunistic infection mortality in adults, a cohort study published in Open Forum Infectious Diseases examined the characteristics of mortality in seven hundred and forty-three HIV-negative patients with cryptococcosis [5]. While cryptococcosis is classically associated with advanced HIV, cases among HIV-negative individuals are rising. In this cohort, the overall mortality rates were relatively low but highly concentrated in the early phases of care, with a two-week mortality of one point four percent, rising to eight point four percent at ten weeks, and twelve point two percent at one year. Multi-variable analyses revealed that advanced age, higher baseline modified Rankin Scale scores, altered mental status, elevated total bilirubin levels, increased peripheral white blood cell counts, reduced serum albumin levels, and elevated creatinine levels were independent risk factors for death. To understand geographic variations, the authors conducted a meta-analysis of four large-scale cohorts, comparing Chinese and Western populations. They found that solid organ transplantation and active malignancy significantly increased the risk of early mortality, with a relative risk of one point five. Meta-regression indicated that the higher early mortality seen in Western cohorts was largely driven by older patient age and a higher prevalence of these severe underlying immunocompromising conditions, highlighting the need for highly tailored clinical risk stratification based on regional patient demographics.

Next, we shift our focus to antimicrobial stewardship, treatment optimization, and the surveillance of drug-resistant pathogens. Writing in the International Journal of Antimicrobial Agents, investigators shared findings from a non-inferiority randomized controlled trial and meta-analysis comparing tegoprazan-amoxicillin dual therapy against an optimized, bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication [2]. The trial, conducted in China, randomized two hundred and fifty-eight treatment-naive patients to either fourteen days of the dual therapy or a quadruple regimen consisting of esomeprazole, amoxicillin, tetracycline, and bismuth. The results showed that tegoprazan-amoxicillin dual therapy failed to demonstrate non-inferiority to the quadruple regimen. Eradication rates in the intention-to-treat analysis were eighty-three percent for the dual therapy versus nearly ninety-one percent for the quadruple therapy. In the per-protocol analysis, the rates were eighty-nine percent versus nearly ninety-six percent, respectively. While both regimens showed similar safety and patient compliance, a subsequent meta-analysis of seven randomized trials confirmed that tegoprazan-amoxicillin dual therapy resulted in a significantly lower eradication rate than bismuth-containing quadruple therapies containing amoxicillin and tetracycline or metronidazole. These findings suggest that despite the simplicity of dual therapy, optimized quadruple therapy should remain the preferred first-line standard of care.

In the same journal, a global surveillance report from the 2024 Antimicrobial Testing Leadership and Surveillance, or ATLAS, programme evaluated the activity of cefiderocol against more than sixteen hundred carbapenem-resistant Enterobacterales isolates [4]. Cefiderocol is a critical siderophore cephalosporin designed to treat highly resistant Gram-negative infections. Globally, overall susceptibility to cefiderocol remained high, at ninety-three percent using Clinical and Laboratory Standards Institute criteria, though it fell to eighty-one percent under the stricter European Committee on Antimicrobial Susceptibility Testing criteria. Crucially, non-susceptibility rates varied dramatically by genus and species. While Klebsiella species demonstrated excellent susceptibility with a non-susceptibility rate of only three and a half percent, Escherichia species showed a high non-susceptibility rate of over twenty-five percent. Species-specific analysis revealed that Enterobacter kobei had a non-susceptibility rate of fifty percent, compared to just seven percent for Enterobacter hormaechei, while Providencia rettgeri exceeded Providencia stuartii. Although unadjusted data suggested that isolates from Asia had the highest rates of resistance, a multivariable logistic regression adjusting for clinical factors revealed that the specific bacterial genus was the dominant independent predictor of resistance, while the geographic effect of Asia was attenuated to a non-significant trend. Alarmingly, genetic profiling of the non-susceptible isolates revealed that nearly forty-four percent did not harbor any identifiable carbapenemase genes, pointing to alternative mechanisms of resistance that clinicians must keep in mind when managing these highly resistant infections.

Our final theme explores how diagnostic advancements and public health delivery models impact infectious disease outcomes and healthcare systems. A systematic review and meta-analysis on behalf of the Hellenic Microbiological Society and the Hellenic Society of Chemotherapy, published in the International Journal of Antimicrobial Agents, evaluated the diagnostic accuracy and clinical utility of rapid molecular testing for severe infections and sepsis [3]. Analyzing forty-nine microbiological and thirty-three clinical studies, the meta-analysis found that rapid molecular tests performed on positive blood cultures achieved an exceptional pooled sensitivity of ninety-seven to ninety-eight percent and a specificity of ninety-nine to one hundred percent for Gram-negative bacteria, Gram-positive bacteria, and yeasts. Clinically, the implementation of these rapid tests shortened the time to pathogen identification by more than twenty-one hours and reduced the time to optimal or adjusted antimicrobial therapy by nearly fourteen hours. Although there was no significant difference in thirty-day mortality, the rapid diagnostic pathways significantly lowered total hospitalization costs, confirming that early, actionable molecular diagnostics are a vital component of cost-effective, high-quality sepsis care.

Meanwhile, in the realm of prevention, a modeling study published in The Journal of Infectious Diseases evaluated the potential population-level benefits and clinical risks of low-barrier, over-the-counter access to daily oral preexposure prophylaxis, or PrEP, using tenofovir disoproxil fumarate and emtricitabine [6]. Using a stochastic network-based model of gay, bisexual, and other men who have sex with men in Atlanta, Georgia, the researchers simulated a ten-year period under varying levels of expanded PrEP access. They estimated that a fifty percent increase in PrEP coverage through low-barrier over-the-counter access would avert over fifteen percent of new HIV infections. However, the model also highlighted significant clinical risks associated with reduced clinical monitoring: patient exposure to renal impairment rose from two point five percent to nearly five percent, hepatitis B virus reactivations reached over two cases per one hundred person-years, and drug resistance events among those who did acquire HIV rose more than twelve-fold, from zero point six eight to eight point four events per one hundred incident infections. Importantly, sensitivity analyses demonstrated that requiring a confirmed HIV-negative status at initiation could reduce drug resistance by more than ninety percent without reducing the overall prevention benefits, while periodic renal monitoring could successfully mitigate the risks of renal toxicity. This study underscores that while low-barrier distribution can greatly expand HIV prevention, preserving basic clinical safety functions is critical to maximizing its net public health benefit.

If you only have time for one paper this week, make it the EMPIRICAL trial published in The Lancet [1]. This multicenter randomized controlled trial provides critical, high-quality evidence on the potential survival benefits of empirical valganciclovir for cytomegalovirus in infants hospitalized with severe HIV-associated pneumonia, showing a significant early survival advantage in time-varying analyses without a signal of increased harm.

Here are the key takeaways from this week in Infectious Disease. First, empirical valganciclovir for cytomegalovirus in infants with severe HIV-associated pneumonia may offer a significant early survival benefit within the first two weeks of treatment, with no evidence of increased severe adverse events [1]. Second, when treating Helicobacter pylori, do not substitute optimized bismuth-containing quadruple therapy with tegoprazan-amoxicillin dual therapy, as the dual regimen failed to establish non-inferiority and demonstrated lower eradication rates in meta-analyses [2]. Third, cefiderocol remains highly active against most carbapenem-resistant Enterobacterales globally, but clinicians must remain vigilant regarding genus- and species-specific resistance, particularly in Escherichia and certain Enterobacter species [4]. Fourth, rapid molecular diagnostics for positive blood cultures significantly accelerate pathogen identification by over twenty-one hours and time to optimal therapy by nearly fourteen hours, reducing overall hospital costs even though thirty-day mortality remained unchanged [3]. And finally, while low-barrier or over-the-counter access to HIV PrEP can significantly reduce community transmission, clinical implementation must preserve safety measures—most notably HIV testing at initiation to prevent drug resistance and basic renal monitoring to avoid toxicity [6].

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.